Details of the Drug

General Information of Drug (ID: DMM7CHK)

Drug Name

Trimethoprim

Synonyms

Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]

Indication

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Approved	[1]

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

290.32

Topological Polar Surface Area (xlogp)

0.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-4 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: 98% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The renal clearance of drug is 51.7-91.3 mL/min [2]
Elimination: Approximately 10-20% of an ingested trimethoprim dose is metabolized, primarily in the liver, while a large portion of the remainder is excreted unchanged in the urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 10 hours [6]
Metabolism: The drug is metabolized via oxidative metabolism to a number of metabolites, the most abundant of which are the demethylated 3'- and 4'- metabolites [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.7461 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.5% [9]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 1.37 mg/mL [3]

Chemical Identifiers

Formula: C14H18N4O3
IUPAC Name: 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
Canonical SMILES: COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
InChI: InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
InChIKey: IEDVJHCEMCRBQM-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5578
ChEBI ID: CHEBI:45924
CAS Number: 738-70-5
DrugBank ID: DB00440
TTD ID: D0AO5H
VARIDT ID: DR00590
INTEDE ID: DR1648
ACDINA ID: D00707

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dihydrofolate reductase (DHFR)	TTYZVDJ	DYR_HUMAN	Modulator	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[11]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trimethoprim

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Trimethoprim and Plazomicin.	Urinary tract infection [GC08]	[64]
-----------

Coadministration of a Drug Treating the Disease Different from Trimethoprim (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Trimethoprim caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[65]
Pioglitazone	DMKJ485	Moderate	Decreased metabolism of Trimethoprim caused by Pioglitazone mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[66]
Bedaquiline	DM3906J	Minor	Increased risk of prolong QT interval by the combination of Trimethoprim and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[67]
Montelukast	DMD157S	Moderate	Decreased metabolism of Trimethoprim caused by Montelukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[68]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Trimethoprim caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[69]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Trimethoprim and Anisindione.	Coagulation defect [3B10]	[70]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Trimethoprim and Drospirenone.	Contraceptive management [QA21]	[71]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Trimethoprim caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[72]
Primidone	DM0WX6I	Moderate	Increased metabolism of Trimethoprim caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[72]
Mephenytoin	DM5UGDK	Moderate	Decreased metabolism of Trimethoprim caused by Mephenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[73]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Trimethoprim caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[74]
Ethotoin	DMXWOCP	Moderate	Decreased metabolism of Trimethoprim caused by Ethotoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[73]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Trimethoprim caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[72]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Trimethoprim caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[72]
Eplerenone	DMF0NQR	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Eplerenone.	Heart failure [BD10-BD1Z]	[75]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Amiloride.	Heart failure [BD10-BD1Z]	[75]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Trimethoprim caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[72]
Efavirenz	DMC0GSJ	Minor	Increased risk of prolong QT interval by the combination of Trimethoprim and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Eprosartan.	Hypertension [BA00-BA04]	[75]
Moexipril	DM26E4B	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Moexipril.	Hypertension [BA00-BA04]	[75]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Captopril.	Hypertension [BA00-BA04]	[75]
Trandolapril	DM4L6EU	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Trandolapril.	Hypertension [BA00-BA04]	[75]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Losartan.	Hypertension [BA00-BA04]	[75]
Fosinopril	DM9NJ52	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Fosinopril.	Hypertension [BA00-BA04]	[75]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and TAK-491.	Hypertension [BA00-BA04]	[75]
Pindolol	DMD2NV7	Minor	Decreased renal excretion of Trimethoprim caused by Pindolol.	Hypertension [BA00-BA04]	[76]
Benazepril	DMH1M9B	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Benazepril.	Hypertension [BA00-BA04]	[75]
Enalapril	DMNFUZR	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Enalapril.	Hypertension [BA00-BA04]	[75]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Perindopril.	Hypertension [BA00-BA04]	[75]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Quinapril.	Hypertension [BA00-BA04]	[75]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Telmisartan.	Hypertension [BA00-BA04]	[75]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Irbesartan.	Hypertension [BA00-BA04]	[75]
Lisinopril	DMUOK4C	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Lisinopril.	Hypertension [BA00-BA04]	[75]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Trimethoprim and Potassium chloride.	Hypo-kalaemia [5C77]	[75]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Trimethoprim and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[77]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Trimethoprim and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[64]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Trimethoprim and Porfimer Sodium.	Lung cancer [2C25]	[78]
Mercaptopurine	DMTM2IK	Moderate	Additive myelosuppressive effects by the combination of Trimethoprim and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[79]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Trimethoprim due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[64]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Trimethoprim caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[72]
Selexipag	DMAHSU0	Moderate	Decreased metabolism of Trimethoprim caused by Selexipag mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[80]
Vardenafil	DMTBGW8	Minor	Increased risk of prolong QT interval by the combination of Trimethoprim and Vardenafil.	Sexual dysfunction [HA00-HA01]	[67]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Trimethoprim caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[81]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Trimethoprim and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[70]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Trimethoprim due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[82]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Trimethoprim and Azathioprine.	Transplant rejection [NE84]	[79]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of nephrotoxicity by the combination of Trimethoprim and Tacrolimus.	Transplant rejection [NE84]	[64]
-----------


⏷ Show the Full List of 47 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Trimethoprim 100 mg tablet	100 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
2	Bergan T, Ortengren B, Westerlund D: Clinical pharmacokinetics of co-trimazine. Clin Pharmacokinet. 1986 Sep-Oct;11(5):372-86. doi: 10.2165/00003088-198611050-00003.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	FDA Approved Drug Products: Trimethoprim oral tablets
6	Health Canada Product Monograph: Trimethoprim oral tablets
7	Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J: Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008 Nov 15;47(10):1298-304. doi: 10.1086/592577.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
12	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
13	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14	Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002 Jun;30(6):631-5.
15	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
16	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
26	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
27	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
28	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
29	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
30	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
31	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
32	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
33	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
34	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
35	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
36	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
37	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
38	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
39	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
40	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
41	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
42	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
43	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
44	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
45	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
46	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
47	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
48	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
49	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
50	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
51	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
52	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
53	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
54	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
55	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
56	Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
57	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
58	Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
59	CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
60	Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
61	Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
62	Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.
63	A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974.
64	Cerner Multum, Inc. "Australian Product Information.".
65	Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
66	Aquilante CL, Kosmiski LA, Bourne DW, et al. "Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone." Br J Clin Pharmacol 75 (2013): 217-26. [PMID: 22625877]
67	Canadian Pharmacists Association.
68	Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
69	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
70	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
71	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
72	Bhatia RS, Uppal R, Malhi R, Behera D, Jindal SK "Drug interaction between rifampicin and cotrimazole in patients with tuberculosis." Hum Exp Toxicol 10 (1991): 419-21. [PMID: 1687853]
73	Gillman MA "Phenytoin toxicity and co-trimazole." Ann Intern Med 102 (1985): 559. [PMID: 3872091]
74	Antoniou T, Gomes T, Mamdani MM, Juurlink DN "Trimethoprim/sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study." Br J Clin Pharmacol 71 (2011): 544-9. [PMID: 21395647]
75	Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666]
76	Ujhelyi MR, Bottorff MB, Schur M, et al. "Aging effects on the organic basic transporter and stereoselective renal clearance." Clin Pharmacol Ther 62 (1997): 117-28. [PMID: 9284847]
77	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
78	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
79	Bailey RR "Leukopenia due to a trimethoprim-azathioprine interaction." N Z Med J 97 (1984): 739. [PMID: 6595562]
80	Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
81	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
82	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".